605
Participants
Start Date
July 31, 2000
Primary Completion Date
October 31, 2004
Study Completion Date
December 31, 2004
epoetin beta [NeoRecormon]
Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
epoetin beta [NeoRecormon]
Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to \<10.5 g/dL had occurred.
Dublin
Taipei
Taoyuan District
Taichung
Tainan City
Brussels
Brussels
Edegem
Herlev
Almada
Sankt Pölten
Roskilde
Linz
Holbæk
Fredericia
Troyes
Bangkok
Berlin
Angoulême
Stockholm
Vimercate
Cinisello Balsamo
Busto Arsizio
Saint-Brieuc
Lecco
Helsingborg
Pavia
Madrid
Madrid
Bordeaux
Tampere
Trieste
Montpellier
Istanbul
Las Palmas de Gran Canaria
Izmir
Padua
Bologna
Jyväskylä
Parma
Tijuana
Valencia
Borås
Chiang Mai
Vandœuvre-lès-Nancy
Jönköping
Véria
Norrköping
Boulogne
Cuernavaca
Karlstad
Colmar
Lyon
Örebro
San Giovanni Rotondo
Paris
Villingen-Schwenningen
Amiens
Napoli
Sundsvall
Würzburg
Moscow
Moscow
Saint Petersburg
Saint Petersburg
Brno
Havířov
Olomouc
Ostrava
Athens
Thessaloniki
Hong Kong
Moscow
Cagliari
Roma
Roma
Roma
Oslo
Gdansk
Kielce
Krakow
Wroclaw
Carnaxide
Lisbon
Porto
Barcelona
Ankara
Belfast
London
Newcastle upon Tyne
Salford
Southampton
Surrey
Hoffmann-La Roche
INDUSTRY